DUBLIN--(BUSINESS WIRE)--The "Global Human Microbiome Market Report by Application Disease Product, Countries and Company Analysis, 2024-2032" report has been added to ResearchAndMarkets.com's offering.
Global Human Microbiome Market will grow US$ 3.05 Billion by 2032 from US$ 0.72 Billion in 2023, with a CAGR of 17.48% during 2023-2032.
The human microbiome is a market with immense potential, including bacteria, archaea, viruses, and eukaryotes inside and outside our bodies. The demand for prebiotics and probiotics is expected to grow significantly due to increased awareness about their role in preventive health measures. Factors driving this growth include the rising geriatric population, the growing prevalence of lifestyle diseases, and government funding for initiatives like the 'Human Microbiome Project' and 'the Earth Microbiome.' These initiatives provide opportunities for market players to research and develop new products, driving market growth during the forecast period.
The human microbiome is a significant area of study and has the potential to revolutionize healthcare. It is related to the rise of lifestyle-related diseases and the aging population, and it directly affects conditions such as diabetes. The International Diabetes Federation 2021 statistics show that there are 52.7 million people aged 20-79 years in Europe with diabetes, which is expected to reach 69 million by 2045. The diversity of gut microbes, particularly the presence of butyrate-producing bacteria, has a significant impact on insulin resistance and the risk of type 2 diabetes, demonstrating the influence of the human microbiome on health. This rise in lifestyle-related illnesses, such as diabetes, will fuel market growth during the upcoming years.
Persephone Biosciences Inc. is developing immune-boosting microbiome therapeutics to prevent and treat COVID-19. They also work on a stool-based diagnostic test to identify patients at risk for severe complications. The pandemic has increased awareness of microbiota therapies and diagnosis, leading to a growing market for these solutions.
Seres Therapeutics Inc. and Nestle Health Science collaborated to jointly commercialize an investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection in Canada and the United States. This collaboration aims to boost market segment growth and strengthen the position of the market players, potentially leading to a new treatment modality.
North American Human Microbiome Market
The United States is the largest market in North America for the human microbiome, followed by Canada. The American Cancer Society predicts that there will be approximately 1,918,030 new cancer diagnoses in the United States in 2022. According to Globocan 2020 data, there are 274,364 new cancer instances, which is expected to reach 400,564 by 2040.
The rising incidence of cancer is expected to drive market expansion due to the role of gut microbiota in regulating tumor therapy and improving patients' response to immunotherapy while reducing the adverse effects of chemotherapeutic drugs. This market expansion is further supported by an increasing number of research studies and the backing of regulatory bodies for investigation. 4D Pharma plc received FDA approval in February 2022 for two Live Biotherapeutics, MRx0005 and MRx0029, as investigational new drugs (IND) to treat Parkinson's disease. These approvals are expected to impact the market's development positively.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 210 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value (USD) in 2023 | $0.72 Billion |
| Forecasted Market Value (USD) by 2032 | $3.05 Billion |
| Compound Annual Growth Rate | 17.4% |
| Regions Covered | Global |
Company Profile: Overview, Recent Developments, Product Portfolio, Revenue
- DuPont
- Evelo Biosciences Inc.
- Finch Therapeutics Group Inc.
- Ginkgo Bioworks
- Seres Therapeutics
- AOBiome
- Astarte Medical
- Axial Biotherapeutics
Application - Global Human Microbiome Market breakup into 2 Viewpoints
- Therapeutics
- Diagnostics
Disease - Global Human Microbiome Market breakup into 7 Viewpoints
- Obesity
- Diabetes
- Autoimmune Disorders
- Cancer
- Gastrointestinal Disorders
- Central Nervous System Disorders
- Other Diseases
Product - Global Human Microbiome Market breakup into 4 Viewpoints
- Probiotics
- Prebiotics
- Symboitics
- Other Products
Geography - Global Human Microbiome breakup of 25 Countries
- North America
- United States
- Canada
- Europe
- France
- Germany
- Italy
- Spain
- United Kingdom
- Belgium
- Netherlands
- Turkey
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Thailand
- Malaysia
- Indonesia
- New Zealand
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- United Arab Emirates
For more information about this report visit https://www.researchandmarkets.com/r/nh19xu
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
